BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 17596404)

  • 1. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis.
    Grempler R; Zibrova D; Schoelch C; van Marle A; Rippmann JF; Redemann N
    Diabetes; 2007 Sep; 56(9):2235-41. PubMed ID: 17596404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of transgenic overexpression of SH2-containing inositol 5'-phosphatase 2 on glucose metabolism and insulin signaling in mice.
    Kagawa S; Soeda Y; Ishihara H; Oya T; Sasahara M; Yaguchi S; Oshita R; Wada T; Tsuneki H; Sasaoka T
    Endocrinology; 2008 Feb; 149(2):642-50. PubMed ID: 18039790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.
    Wada T; Sasaoka T; Funaki M; Hori H; Murakami S; Ishiki M; Haruta T; Asano T; Ogawa W; Ishihara H; Kobayashi M
    Mol Cell Biol; 2001 Mar; 21(5):1633-46. PubMed ID: 11238900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lipid phosphatase SHIP2 controls insulin sensitivity.
    Clément S; Krause U; Desmedt F; Tanti JF; Behrends J; Pesesse X; Sasaki T; Penninger J; Doherty M; Malaisse W; Dumont JE; Le Marchand-Brustel Y; Erneux C; Hue L; Schurmans S
    Nature; 2001 Jan; 409(6816):92-7. PubMed ID: 11343120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes.
    Sasaoka T; Hori H; Wada T; Ishiki M; Haruta T; Ishihara H; Kobayashi M
    Diabetologia; 2001 Oct; 44(10):1258-67. PubMed ID: 11692174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2) on insulin signaling and glucose metabolism in mice.
    Fukui K; Wada T; Kagawa S; Nagira K; Ikubo M; Ishihara H; Kobayashi M; Sasaoka T
    Diabetes; 2005 Jul; 54(7):1958-67. PubMed ID: 15983195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation.
    Grempler R; Leicht S; Kischel I; Eickelmann P; Redemann N
    FEBS Lett; 2007 Dec; 581(30):5885-90. PubMed ID: 18061583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.
    Suwa A; Yamamoto T; Sawada A; Minoura K; Hosogai N; Tahara A; Kurama T; Shimokawa T; Aramori I
    Br J Pharmacol; 2009 Oct; 158(3):879-87. PubMed ID: 19694723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual role of SRC homology domain 2-containing inositol phosphatase 2 in the regulation of platelet-derived growth factor and insulin-like growth factor I signaling in rat vascular smooth muscle cells.
    Sasaoka T; Kikuchi K; Wada T; Sato A; Hori H; Murakami S; Fukui K; Ishihara H; Aota R; Kimura I; Kobayashi M
    Endocrinology; 2003 Sep; 144(9):4204-14. PubMed ID: 12933696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome.
    Buettner R; Ottinger I; Gerhardt-Salbert C; Wrede CE; Schölmerich J; Bollheimer LC
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1871-8. PubMed ID: 17327370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
    Sasaoka T; Wada T; Tsuneki H
    Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes.
    Ikubo M; Wada T; Fukui K; Ishiki M; Ishihara H; Asano T; Tsuneki H; Sasaoka T
    Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E157-64. PubMed ID: 19001549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane localization of Src homology 2-containing inositol 5'-phosphatase 2 via Shc association is required for the negative regulation of insulin signaling in Rat1 fibroblasts overexpressing insulin receptors.
    Ishihara H; Sasaoka T; Ishiki M; Wada T; Hori H; Kagawa S; Kobayashi M
    Mol Endocrinol; 2002 Oct; 16(10):2371-81. PubMed ID: 12351701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR/SREBP1 pathway and ROS production in HepG2 cells.
    Gorgani-Firuzjaee S; Meshkani R
    Free Radic Biol Med; 2015 Dec; 89():679-89. PubMed ID: 26456051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain.
    Soeda Y; Tsuneki H; Muranaka H; Mori N; Hosoh S; Ichihara Y; Kagawa S; Wang X; Toyooka N; Takamura Y; Uwano T; Nishijo H; Wada T; Sasaoka T
    Mol Endocrinol; 2010 Oct; 24(10):1965-77. PubMed ID: 20829391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of denervation-induced insulin resistance by SHIP2 protein synthesis blockade.
    Bertelli DF; Ueno M; Amaral ME; Toyama MH; Carneiro EM; Marangoni S; Carvalho CR; Saad MJ; Velloso LA; Boschero AC
    Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E679-87. PubMed ID: 12453826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between the SH2-containing inositol polyphosphate 5-Phosphatase 2 (SHIP2) and the adaptor protein APS has an impact on biochemical properties of both partners.
    Onnockx S; De Schutter J; Blockmans M; Xie J; Jacobs C; Vanderwinden JM; Erneux C; Pirson I
    J Cell Physiol; 2008 Jan; 214(1):260-72. PubMed ID: 17620296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes.
    Suwa A; Kurama T; Yamamoto T; Sawada A; Shimokawa T; Aramori I
    Eur J Pharmacol; 2010 Sep; 642(1-3):177-82. PubMed ID: 20558154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SH2-containing inositol 5'-phosphatase 2 selectively impairs hypothalamic insulin signalling and regulation of food intake in mice.
    Ichihara Y; Wada T; Soeda Y; Ishii Y; Sasahara M; Tsuneki H; Sasaoka T
    J Neuroendocrinol; 2013 Apr; 25(4):372-82. PubMed ID: 23286299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse.
    Dubois E; Jacoby M; Blockmans M; Pernot E; Schiffmann SN; Foukas LC; Henquin JC; Vanhaesebroeck B; Erneux C; Schurmans S
    Cell Signal; 2012 Nov; 24(11):1971-80. PubMed ID: 22750293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.